Skip to main content
SpringerLink
Log in

Fluoxetine for the Treatment of Fatigue in Primary Biliary Cirrhosis: A Randomized, Double-Blind Controlled Trial

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Fatigue is a common symptom in primary biliary cirrhosis (PBC). In animal models of cholestasis, abnormalities in serotonin neurotransmission are observed with fatigue. The role of selective serotonin reuptake inhibitors in fatigue-related PBC, however, is unknown. A double-blind, placebo-controlled study design was conducted to determine the safety and efficacy of fluoxetine for the treatment of fatigue in PBC. Patients were randomized to fluoxetine, 20 mg daily, or matched placebo for 8 weeks’ duration. Fatigue was assessed by the Fisk Fatigue Impact Scale (FFIS). The primary study endpoint was a ≥50% reduction in overall FFIS score at the end of treatment. Health-related quality of life (HRQL) was assessed as a secondary endpoint. Among 220 consecutively screened patients, only 18 (9%) eligible individuals were randomized to fluoxetine (n=10) or placebo (n=8) for 8 weeks. Baseline variables including median FFIS scores (52 vs 42; P=0.21) were similar between treatment arms (P > 0.05). After 8 weeks of therapy, no statistically significant change in median FFIS score was observed in the fluoxetine group. Median FFIS score in the placebo group was reduced (42 to 28), but not statistically significant. No difference in HRQL was observed between treatment arms after 8 weeks. Fourteen (78%) patients completed therapy, while four (22%) individuals withdrew from the trial. Three of the four patients had drug-related adverse events with fluoxetine. In this study, fluoxetine did not improve fatigue in PBC and was associated with adverse events.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Sherlock S, Scheuer PJ (1973) The presentation and diagnosis of 100 patients with primary biliary cirrhosis. N Engl J Med 289:674–678

    Article  PubMed  CAS  Google Scholar 

  2. Christensen E, Crowe J, Doniach D, Popper H, Ranek L, Rodes J, Tygstrup N, Williams R (1980) Clinical pattern and course of disease in primary biliary cirrhosis based on an analysis of 236 patients. Gastroenterology 78:236–246

    PubMed  CAS  Google Scholar 

  3. Kapelman B, Schaffner F (1981) The natural history of primary biliary cirrhosis. Semin Liver Dis 4:273–281

    Article  Google Scholar 

  4. James O, Macklon AF, Watson A (1981) Primay biliary cirrhosis—a revised clinical spectrum. Lancet 13:1278–1281

    Google Scholar 

  5. Crowe J, Christensen E, Doniach D, Popper H, Tygstrup N, Williams R (1985) Early features of primary biliary cirrhosis: An analysis of 85 patients. Am J Gastroenterol 80:466–468

    PubMed  CAS  Google Scholar 

  6. Nyberg A, Loof L (1989) Primary biliary cirrhosis: Clinical features and outcome with special reference to asymptomatic disease. Scand J Gastroenterol 24:57–64

    PubMed  CAS  Google Scholar 

  7. Witt-Sullivan H, Heathcote J, Cauch K, Blendis L, Ghent C, Katz A, Milner R, Pappas SC, Rankin J, Wanless IR (1990) The demography of primary biliary cirrhosis in Ontario, Canada. Hepatology 12:98–105

    PubMed  CAS  Google Scholar 

  8. Poupon RE, Poupon R, Balkau B (1994) Ursodiol for the long-term treatment of primary biliary cirrhosis. N Engl J Med 330:1342–1347

    Article  PubMed  CAS  Google Scholar 

  9. Heathcote EJ, Cauch-Dudek K, Walker V, Bailey RJ, Blendis LM, Ghent CN, Michieletti P, Minuk GY, Pappas SC, Scully LJ (1994) The Canadian multicentre double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhsois. Hepatology 19:1149–1156

    Article  PubMed  CAS  Google Scholar 

  10. Lindor KD, Dickson ER, Baldus WP, Jorgensen RA, Ludwig J, Murtaugh PA, Harrison JM, Wiesner RH, Anderson ML, Lange SM (1994) Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 106:1284–1290

    PubMed  CAS  Google Scholar 

  11. Combes B, Carithers RL Jr, Maddrey WC, Lin D, McDonald MF, Wheeler DE, Eigenbrodt EH, Munoz SJ, Rubin R, Garcia-Tsao G (1995) A randomized, double-blind placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 22(3):759–766

    Article  PubMed  CAS  Google Scholar 

  12. Pares A, Caballeria L, Rodes J, Bruguera M, Rodrigo L, Garcia-Plaza A, Berenguer J, Rodriguez-Martinez D, Mercader J, Velicia R (2000) Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: Results of a double-blind controlled multicentric trial. J Hepatol 32(4):561–566

    Article  PubMed  CAS  Google Scholar 

  13. Prince M, Chetwynd A, Newman W, Metcalf JV, James OFW (2002) Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: Follow-up for up to 28 years. Gastroenterology 123:1044–1051

    Article  PubMed  Google Scholar 

  14. Cauch-Dudek K, Abbey S, Stewart DE, Heathcote EJ (1998) Fatigue in primary biliary cirrhosis. Gut 43(5):705–710

    Google Scholar 

  15. Huet PM, Deslauriers J, Tran A, Faucher C, Charbonneau J (2000) Impact of fatigue on the quality of life of patients with primary biliary cirrhosis. Am J Gastroenterol 95(3):760–767

    Article  PubMed  CAS  Google Scholar 

  16. Prince MI, James OF, Holland NP, Jones DE (2000) Validation of a fatigue impact score in primary biliary cirrhosis: Towards a standard for clinical and trial use. J Hepatol 32:368–373

    Article  PubMed  CAS  Google Scholar 

  17. Goldblatt J, Taylor PJ, Lipman T, et al. (2002) The true impact of fatigue in primary biliary cirrhosis: A population study. Gastroenterology 122:1235–1241

    Article  PubMed  Google Scholar 

  18. Prince MI, Mitchison HC, Ashley D, et al. (2003) Oral antioxidant supplementation for fatigue associated with primary biliary cirrhosis: Results of a multicentre, randomized, placebo-controlled, cross-over trial. Aliment Pharmacol Ther 17:137–143

    Article  PubMed  CAS  Google Scholar 

  19. Watson JP, Jones DE, James OF, Cann PA, Bramble MG (1999) Case report: Oral antioxidant therapy for the treatment of primary biliary cirrhosis: A pilot study. J Gastroenterol Hepatol 14:1034–1040

    Article  PubMed  CAS  Google Scholar 

  20. Theal JJ, Toosi MN, Girlan L, Heslegrave RJ, Huet PM, Burak KW, Swain M, Tomlinson GA, Heathcote EJ (2005) A randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue. Hepatology 41:1305–1312.

    Google Scholar 

  21. Radloff LS (1977) CES-D scale: A self-report depression scale for research in the general population. Psychol Meas 1:385–401

    Google Scholar 

  22. Fisk JD, Ritvo PG, Ross L, et al. (1994) Measuring the functional impact of fatigue: Initial validation of the fatigue impact scale. Clin Infect Dis 18:S79–S83

    PubMed  Google Scholar 

  23. Younossi ZM, Guyatt G, Kiwi M, Boparai N, King D (1999) Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut 45:295–300

    Article  PubMed  CAS  Google Scholar 

  24. Younossi ZM, Kiwi ML, Boparai N, Price LL, Guyatt G (2000) Cholestatic liver diseases and health-related quality of life. Am J Gastroenterol 95:497–502

    Article  PubMed  CAS  Google Scholar 

  25. Rannard A, Buck D, Jones DEJ, James OFW, Jacoby A (2000) Assessing quality of life in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2:164–174

    Article  Google Scholar 

  26. Swain MG (2000) Fatigue in chronic disease. Clin Sci (Lond) 99:1–8

    Article  CAS  Google Scholar 

  27. Demitrack MA, Dale JK, Straus SE, Laue L, Listwak SJ, Kruesi MJ, Chrousos GP, Gold PW (1991) Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. J Clin Endocrinol Metab 73:1224– 1234

    Article  PubMed  CAS  Google Scholar 

  28. Jones EA (1999) Relief from profound fatigue associated with chronic liver disease by long-term ondansetron therapy. Lancet 354:397

    Article  PubMed  CAS  Google Scholar 

  29. Gutierrez MA, Garcia ME, Rodriguez JA, Mardonez G, Jacobelli S, Rivero S (1999) Hypothalamic-pituitary-adrenal axis function in patients with active rheumatoid arthritis: A controlled study using insulin hypoglycemia stress test and prolactin stimulation. J Rheumatol 26:277–281

    PubMed  CAS  Google Scholar 

  30. Klapps P, Seyfert S, Fischer T, Scherbaum WA (1992) Endocrine function in multiple sclerosis. Acta Neurol Scand 85:353–357

    Article  PubMed  CAS  Google Scholar 

  31. Swain MG, Patchev V, Vergalla J, Chrousos G, Jones EA (1993) Suppression of hypothalamic-pituitary-adrenal axis responsiveness to stress in a rat model of acute cholestasis. J Clin Invest 91:1903–1908

    Article  PubMed  CAS  Google Scholar 

  32. Swain MG, Maric M (1995) Defective corticotropin-releasing hormone mediated neuroendocrine and behavioural responses in cholestatic rats: Implications for cholestatic liver disease-related sickness behaviours. Hepatology 22:1560–1564

    Article  PubMed  CAS  Google Scholar 

  33. Swain MG, Le T (1998) Chronic cholestasis in rats induces anhedonia and a loss of social interest. Hepatology 28(1):6–10

    Article  PubMed  CAS  Google Scholar 

  34. Burak KW, Le T, Swain MG (2002) Increased sensitivity to the locomotor-activating effects of corticotropin-releasing hormone in cholestatic rats. Gastroenterology 122:681–688

    Article  PubMed  CAS  Google Scholar 

  35. Swain MG, Beck P, Rioux K, Le T (1998) Augmented interleukin-1β-induced depression of locomotor activity in cholestatic rats. Hepatology 28:1561–1565

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroneterology & Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA

    Jayant A. Talwalkar, Jessica J. Donlinger, Andrea A. Gossard, Jill C. Keach, Roberta A. Jorgensen, Janice C. Petz & Keith D. Lindor

  2. Division of Gastroenterology/Hepatology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, Minnesota, 55905, USA

    Jayant A. Talwalkar

Authors
  1. Jayant A. Talwalkar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jessica J. Donlinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrea A. Gossard
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jill C. Keach
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Roberta A. Jorgensen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Janice C. Petz
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Keith D. Lindor
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jayant A. Talwalkar.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Talwalkar, J.A., Donlinger, J.J., Gossard, A.A. et al. Fluoxetine for the Treatment of Fatigue in Primary Biliary Cirrhosis: A Randomized, Double-Blind Controlled Trial. Dig Dis Sci 51, 1985–1991 (2006). https://doi.org/10.1007/s10620-006-9397-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-006-9397-5

Keywords

Search

Navigation